Pancreatic Cancer Research

ResearcherMaastricht UniversityActive in the last 2 years

Stefan A.W. Bouwense

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7600-9429; OpenAlex author ID A5016920397. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
57
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 6 papers · 2026: 7 papers

Papers 15

  1. Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2026.100311↗
  2. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2026.117352↗
  3. Mass spectrometry imaging in spatial biology of pancreatic cancer. Last author DOI 10.1039/d5an01264c↗
  4. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  5. Pain prevalence and intensity in advanced pancreatic cancer: a nationwide cohort study. Co-author DOI 10.1097/j.pain.0000000000004059↗
  6. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  7. Patient Experiences of Oncological Care in Comprehensive Cancer Networks: A Qualitative Study in Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-9113970/v1↗
  8. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  9. Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based … Co-author DOI 10.1016/j.ejca.2025.115385↗
  10. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  11. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  12. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  13. Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. Co-author DOI 10.6004/jnccn.2024.7091↗
  14. Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care. Co-author DOI 10.3390/cancers15143546↗
  15. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33916↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Johanna W. Wilmink · 8 shared papers, 2022–2026 · strength 1.48
  2. Judith de Vos‐Geelen · 7 shared papers, 2022–2026 · strength 1.30
  3. Marjolein Y.V. Homs · 6 shared papers, 2022–2026 · strength 1.11
  4. Marc G. Besselink · 6 shared papers, 2022–2026 · strength 1.08
  5. Ignace H. J. T. de Hingh · 5 shared papers, 2025–2026 · strength 0.96
  6. Merlijn U.J.E. Graus · 4 shared papers, 2023–2026 · strength 0.84
  7. Bas Groot Koerkamp · 5 shared papers, 2022–2025 · strength 0.79
  8. Hanneke W.M. van Laarhoven · 4 shared papers, 2022–2026 · strength 0.76
  9. Hjalmar C. van Santvoort · 4 shared papers, 2025–2026 · strength 0.75
  10. Steven W.M. Olde Damink · 2 shared papers, 2026 · strength 0.69
  11. Marion B.M. van der Kolk · 3 shared papers, 2025–2026 · strength 0.63
  12. Martijn W.J. Stommel · 3 shared papers, 2025 · strength 0.54
  13. Vincent Erwin de Meijer · 3 shared papers, 2022–2025 · strength 0.52
  14. Casper H.J. van Eijck · 3 shared papers, 2025 · strength 0.51
  15. J. Sven D. Mieog · 3 shared papers, 2023–2025 · strength 0.48
  16. Quisette P. Janssen · 3 shared papers, 2022–2025 · strength 0.45
  17. Bert A. Bonsing · 3 shared papers, 2022–2025 · strength 0.45
  18. Aniek E. van Diepen · 2 shared papers, 2025–2026 · strength 0.45
  19. Simone Augustinus · 2 shared papers, 2025–2026 · strength 0.42
  20. Ruth A.L. Willems · 2 shared papers, 2023–2026 · strength 0.39
  21. Izaak Quintus Molenaar · 2 shared papers, 2025 · strength 0.39
  22. Nadine Nieste · 1 shared paper, 2026 · strength 0.39
  23. Thomas F. Stoop · 2 shared papers, 2025 · strength 0.35
  24. Evelien J.M. de Jong · 2 shared papers, 2022–2025 · strength 0.34
  25. Lydia G. van der Geest · 2 shared papers, 2022–2025 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.